Therapeutic advances in neurological disorders · 2021

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).

СтатьяОбзорНазвание и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wiendl Heinz, Gold Ralf, Berger Thomas, Derfuss Tobias, Linker Ralf, Mäurer Mathias, Aktas Orhan, Baum Karl, Berghoff Martin, Bittner Stefan, Chan Andrew, Czaplinski Adam, Deisenhammer Florian, Di Pauli Franziska, Du Pasquier Renaud, Enzinger Christian, Fertl Elisabeth, Gass Achim, Gehring Klaus, Gobbi Claudio, Goebels Norbert, Guger Michael, Haghikia Aiden, Hartung Hans-Peter, Heidenreich Fedor, Hoffmann Olaf, Kallmann Boris, Kleinschnitz Christoph, Klotz Luisa, Leussink Verena I, Leutmezer Fritz, Limmroth Volker, Lünemann Jan D, Lutterotti Andreas, Meuth Sven G, Meyding-Lamadé Uta, Platten Michael, Rieckmann Peter, Schmidt Stephan, Tumani Hayrettin, Weber Frank, Weber Martin S, Zettl Uwe K, Ziemssen Tjalf, Zipp Frauke, ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG)

Аннотация

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).

Ошибки и ограничения

Аннотация